Sino Medical Sciences Technology

received NMPA registration for a new-generation drug-eluting coronary stent system in February 2026, developed based on international frontier research for percutaneous coronary intervention (PCI).

Country: China
Ticker: 688108.SH

Drug-eluting coating NMPA registered cn

Coverage

	CN	EU	US
regenerative-personalized	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Funding	The company has secured funding through means such as equity buyback plans (e.g., CNY 30 million announced in Feb 2026) and maintains R&D funding allocation from its operational capital and proceeds.	www1.hkexnews.hk
Capacity	Manufacturing facilities in Tianjin and Suzhou span over 25,000 sq.m., including over 4,500 sq.m. of qualified cleanrooms.	www1.hkexnews.hk
Certification	The company holds various certifications, including ISO 14644-1:2015 standards for its facilities and multiple product-specific registrations and EU MDR approvals.	sinomed.com · www1.hkexnews.hk
Regulatory approval	The company received NMPA registration for coronary interventional products, EU MDR approvals, and various international market registrations (e.g., Colombia, Indonesia, Mexico) for its stents and balloon catheters.	qiye.qizhidao.com · marketscreener.com · sinomed.com · www1.hkexnews.hk
Production site	Production facilities are located in Tianjin and Suzhou, China.	www1.hkexnews.hk
Headcount	445 to 691 employees.	qiye.qizhidao.com · widgets.macroaxis.com · futunn.com
Revenue	RMB 139.74 million (Q1 2026); RMB 525 million (full year 2025).	it.marketscreener.com · news.futunn.com

Independent sources: futunn.com · it.marketscreener.com · marketscreener.com · news.futunn.com · qiye.qizhidao.com · widgets.macroaxis.com · www1.hkexnews.hk

Technologies

Name	Cluster	Risk
Medical devices with biointerface	regenerative-personalized	Medium	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.